Stockscreener 앱 받기
0.2417
7.92%
-0.0208
시장 영업 전:
.24
-0.0017
-0.70%
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
OTLK Technical Analysis | Trend, Signals & Chart Patterns | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Reports Closing of $5.0 Million Registered Direct Offering - VisionMonday.com
Outlook Therapeutics launches public offering; shares down - MSN
OTLK Price Today: Outlook Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Certain Options of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Outlook Therapeutics (OTLK) joint holders report 4.99% stake after SPA - Stock Titan
Outlook Therapeutics closes $5M registered direct offering By Investing.com - Investing.com India
Outlook Therapeutics stock slides after pricing $5M offering - MSN
Outlook Therapeutics announces $5M registered direct offering priced at-the-market - MSN
Outlook Therapeutics Announces New Equity Financing Transaction - TipRanks
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics closes $5M registered direct offering - Investing.com
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - The Manila Times
Outlook Therapeutics (NASDAQ: OTLK) raises $5M via 16.13M-share deal - Stock Titan
Outlook Therapeutics raises $5M in registered direct offering By Investing.com - Investing.com India
Outlook Therapeutics drops 17%, prices $13M stock offering - MSN
Outlook Therapeutics Inc. posts 24.4% EPS miss, $1.4T revenueVerified Stock Signals - Xã Thanh Hà
Outlook Therapeutics (OTLK) Announces $5M Share Offering - GuruFocus
Outlook Therapeutics raises $5M in registered direct offering - Investing.com
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Outlook sells 16.1M shares at 31 cents to raise $5M in direct sale - Stock Titan
Outlook Therapeutics completes FDA dispute resolution meeting By Investing.com - Investing.com India
Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug - TipRanks
Outlook Therapeutics (OTLK) Advances Regulatory Discussions with FDA - GuruFocus
Outlook Therapeutics completes FDA Federal Dispute Resolution meeting for ONS-5010; formal decision expected May 2026 - TradingView
Outlook Therapeutics (OTLK) finishes FDA FDR meeting; ONS-5010 decision expected May 2026 - Stock Titan
Outlook Therapeutics completes FDA dispute resolution meeting - Investing.com
Outlook Therapeutics completes federal dispute resolution (FDR) meeting with FDA for ONS-5010/Lytenava(TM) (bevacizumab-vikg) - marketscreener.com
Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg) - TradingView
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - ChartMill
OTLK | Outlook Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakouts Watch: Will Outlook Therapeutics Inc benefit from AI trends2026 Big Picture & Low Drawdown Trading Strategies - baoquankhu1.vn
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Hold Rating, Maintains Target Price $0.5 - Moomoo
Outlook Therapeutics files dispute resolution request with FDA By Investing.com - Investing.com India
Outlook Therapeutics’ Formal Dispute Resolution for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA for Wet AMD Approval Pathway 1 - Minichart
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - Sahm
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Sahm
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010 - TipRanks
FDA accepts Outlook Therapeutics (NASDAQ: OTLK) dispute request on LYTENAVA - Stock Titan
Outlook Therapeutics request for FDA dispute resolution on ONS-5010 accepted - Traders Union
Outlook Therapeutics (OTLK) Seeks FDA Review for ONS-5010 Approval - GuruFocus
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
0.14%
0.48%
자본화:
|
볼륨(24시간):